Drug Patents owned by Janssen Pharms

1. List of Invega Hafyera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143693 JANSSEN PHARMS Dosing regimen for missed doses for long-acting injectable paliperidone esters
Apr, 2036

(13 years from now)

US11324751 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(18 years from now)

US11304951 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Aug 30, 2024

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 18 May, 2015

Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago; Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose; Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA HAFYERA before it's patent expiration?
More Information on Dosage

2. List of Invega Sustenna drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906 JANSSEN PHARMS Dosing regimen associated with long acting injectable paliperidone esters
Jan, 2031

(7 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: Treatment of schizophrenia; Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; Dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loading doses of paliperidone palmitate followed by maintenance dose(s); Dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA SUSTENNA before it's patent expiration?
More Information on Dosage

3. List of Invokamet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(1 year, 6 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(2 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's patent expiration?
More Information on Dosage

4. List of Invokamet Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(1 year, 6 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(2 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's patent expiration?
More Information on Dosage

5. List of Invokana drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(2 years from now)

US10617668 JANSSEN PHARMS Pharmaceutical formulations
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

Market Authorisation Date: 29 March, 2013

Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; Treatment of type 2 diabetes mellitus with 300 mg canagliflozin per day; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; Treatment of type 2 diabetes mellitus with 100 mg canagliflozin per day

Dosage: TABLET;ORAL

How can I launch a generic of INVOKANA before it's patent expiration?
More Information on Dosage

6. List of Levaquin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6806256 JANSSEN PHARMS Taste masked liquid pharmaceutical compositions
Feb, 2022

(11 months ago)

US6806256

(Pediatric)

JANSSEN PHARMS Taste masked liquid pharmaceutical compositions
Aug, 2022

(5 months ago)

Drugs and Companies using LEVOFLOXACIN ingredient

Market Authorisation Date: 21 October, 2004

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of LEVAQUIN before it's patent expiration?
More Information on Dosage

7. List of Ponvory drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(1 year, 9 months from now)

US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives
Nov, 2024

(1 year, 9 months from now)

US8273779 JANSSEN PHARMS Thiazolidin 4-one derivatives
Dec, 2025

(2 years from now)

US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist
Dec, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titration schedule followed by a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage

8. List of Spravato drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592207 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2027

(4 years from now)

US8785500 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2033

(10 years from now)

US11446260 JANSSEN PHARMS Pharmaceutical composition of S-ketamine hydrochloride
Mar, 2034

(11 years from now)

US11311500 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(12 years from now)

US10869844 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(12 years from now)

US11173134 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 5, 2024
New Indication (I) Jul 31, 2023

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition twice per week in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine twice per week as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase in conjunction with an oral antidepressent; Treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant; Treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks

Dosage: SPRAY;NASAL

More Information on Dosage

9. List of Xarelto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(1 year, 6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415053 JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
Nov, 2024

(1 year, 9 months from now)

US7157456

(Pediatric)

JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Feb, 2025

(2 years from now)

US9415053

(Pediatric)

JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
May, 2025

(2 years from now)

US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Feb, 2034

(11 years from now)

US9539218

(Pediatric)

JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Aug, 2034

(11 years from now)

US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events
Jan, 2039

(16 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events
Jul, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Aug 23, 2024
M Mar 10, 2023
Pediatric Exclusivity (PED) Apr 11, 2023

Drugs and Companies using RIVAROXABAN ingredient

Market Authorisation Date: 01 July, 2011

Treatment: Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Treatment of deep vein thrombosis (dvt); Reduction of risk of major cardiovascular events (cv death, mi, and stroke) in chronic cad or pad; Prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding; Prophylaxis of thromboembolic diseases in pediatric patients aged 2 years and older with congenital heart disease who have undergone the fontan procedure and a body weight of >=50 kg; Treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of 30 kg to 49.9 kg after at least 5 days of initial parenteral anticoagulant treatment; Reduction in the risk of recurrence of deep vein thrombosis (dvt) and/or pulmonary embolism (pe) in patients at continued risk for recurrent dvt and/or after completion of initial treatment lasting at least 6 months; Prophylaxis of deep vein thrombosis (dvt); Reduction of risk of major cardiovascular events (cardiovascular death, myocardial infarction and stroke) in patients with cad; Reduction of risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of vascular etiology) in patients with pad; Treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of >=50 kg after at least 5 days of initial parenteral anticoagulant treatment; Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; After completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; Prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; Reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily

Dosage: TABLET;ORAL

How can I launch a generic of XARELTO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in